Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OsvaRen vs Renagel in haemodialysis patients with hyperphosphataemia
2006-002589-20Phase 3Completed
- Sponsor
- Fresenius Medical Care
- Start
- Sep 2007
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial in hyperphosphatemia and chronic kidney disease (CKD) comparing OsvaRen with Renagel (2 arms). Primary endpoint: Serum phosphorus at Week 25. Started Sep 2007; status: completed.
02
Drugs
calcium acetate + magnesium carbonatesevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2006-002589-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002589-20.